Johnson & Johnson (J&J) has announced plans to construct a state-of-the-art biologics plant in Wilson, North Carolina, with construction set to commence in the first half of 2025. This ambitious project comes with a substantial investment exceeding $2 billion, aimed at bolstering J&J's supply chain
Ireland’s biopharma industry stands as an indispensable pillar of the nation’s economy, evidencing significant contributions and future growth potential. In 2022 alone, the sector accounted for 32% of the country's industrial exports, amassing over €42 billion, and directly employed nearly 50,000
Cell and gene therapies (C>s) have emerged as revolutionary treatments, particularly for rare diseases with limited treatment options. The rapid growth in demand for these personalized medicines has posed significant challenges for the industry, particularly in maintaining product consistency,
The biopharmaceutical industry is increasingly recognizing sustainability as a critical component of its future success. According to Cytiva’s 2024 Global Biopharma Sustainability Review, which surveyed 800 industry professionals from 18 countries, sustainability has shifted from a secondary
In a significant step towards fostering environmental responsibility in the pharmaceutical sector, Tower Cold Chain has launched a new sustainability hub designed to help pharmaceutical manufacturers improve their environmental, social, and governance (ESG) practices. This initiative highlights the
Afton Scientific is making headlines with its substantial investment of over $200 million to expand its biopharmaceutical manufacturing facility in Albemarle County, Virginia. This significant expansion not only highlights the company's commitment to growth but also underscores the robust health of
